In our investigation of ESCC's sensitivity to mTOR inhibitors, we initially assessed the half-maximal inhibitory concentration (IC50) of rapamycin across different esophageal cancer cell lines. This evidence concerns the gene MTOR and esophageal squamous cell carcinoma.